01940nas a2200277   4500000000100000008004100001260001200042653001800054653002400072653002000096653003200116100001500148700001300163700001300176700001600189700001400205700001200219700001500231700001400246245008100260856006700341300000900408490000700417520122400424022001401648       2024                            d  c02/202410aFrench Guiana10aChromoblastomycosis10aendemic mycoses10aNeglected Tropical Diseases1 aValentin J1 aGrotta G1 aMuller T1 aBourgeois P1 aAlsibai K1 aDemar M1 aCouppié P1 aBlaizot R00aChromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.  uhttps://www.mdpi.com/2309-608X/10/3/168/pdf?version=1708592059  a1-120 v103 a<p>Chromoblastomycosis (CBM) is a chronic neglected fungal disease, usually met in tropical areas. French Guiana is a South American territory with limited epidemiological data. This retrospective study concerned all patients with CBM proven by at least one paraclinical examination and diagnosed in French Guiana between 1950 and 2023. In total, 23 patients were included, mostly males (87%) of Creole origin, living in the coastal region (87%) and involved in outdoor occupations (74%). Lesions were mostly observed on the lower limbs (78.3%), with a median time to diagnosis of four years. Laboratory tests included positive direct microscopic examinations (78.3%) and mycological cultures (69.6%), identifying 14 cases of and one case of Various treatments were employed, including antifungals, surgery and combinations of both. In conclusion, CBM in French Guiana involves a different population than other subcutaneous mycoses such as Lobomycosis or Paracoccidioidomycosis, mostly found in the forest hinterland. Surgery should be recommended for recent and limited lesions. Itraconazole and terbinafine should systematically be proposed, either in monotherapy or in combination with surgery or cryotherapy.</p>
  a2309-608X